Treatment of Severe Systemic Lupus Erythematosus Without Renal Involvement
This protocol addresses severe systemic lupus erythematosus (SLE) presenting with major
organ-threatening disease in the absence of renal involvement — a high-acuity subset
requiring prompt intervention guided by a structured approach.
This Protocol Applies When
- Major organ-threatening disease is present: cerebritis, myelitis, pneumonitis, or mesenteric vasculitis
- Thrombocytopenia with platelets <20 × 10&sup9;/L
- TTP-like disease or acute haemophagocytic syndrome
- Rash involving >18% of body surface area
- SLEDAI >12 or at least one BILAG A manifestation
Treatment Approach (Partial Overview)
Management of this severe, non-renal presentation incorporates an antimalarial agent as a
cornerstone alongside intravenous corticosteroid pulses for acute control — the complete
regimen, including further agent selection and sequencing, is available in the full protocol.
Treatment Targets
SLEDAI score of 0 (remission), or SLEDAI ≤4 (low disease activity state) where full remission is not achievable.
References
DOI: 10.1136/ard-2023-224762
- Severe disease: major organ threatening disease (cerebritis, myelitis, pneumonitis, mesenteric vasculitis); thrombocytopenia with platelets<20×10&sup9;/L; TTP-like disease or acute haemophagocytic syndrome; rash>18% BSA SLEDAI>12; ≥1 BILAG A manifestations.
- Hydroxychloroquine is recommended for all patients (1b/A), unless contraindicated, at a target dose of 5 mg/kg real body weight/day (2b/B), but individualised based on risk for flare (2b/B) and retinal toxicity.
- In patients with moderate-to-severe disease, pulses of intravenous methylprednisolone (125–1000 mg per day, for 1–3 days) (3b/C) can be considered.
- Early SLE diagnosis (including serological assessment), regular screening for organ involvement (especially nephritis), prompt initiation of treatment aiming at remission (or low disease activity if this is not possible) and strict adherence to treatment are essential to prevent flares and organ damage, improve prognosis and enhance quality of life.
View source ↗